Betta Pharmaceuticals Gains FDA Approval for Clinical Trial of BPI-460372
China’s Betta Pharmaceuticals (SHE: 300558) has announced receiving clinical trial approval from the US FDA...
Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released its financial results for Q4 and the...
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates
US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1%...
Kelun’s SKB264 Receives Breakthrough Therapy Designation for Lung Cancer
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody-drug conjugate (ADC) SKB264,...
Hengrui’s Camrelizumab-Apatinib Combo Approved for Liver Cancer in China
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...
Yiling Pharmaceutical’s G201-Na Accepted for Review by China’s NMPA for Prostate Cancer
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...
Zhaoke Ophthalmology’s Cyclosporine A Eye Gel Nears Market Approval in China
Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...
Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes
Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...
Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417
Beijing’s municipal Healthcare Security Administration (HSA) bureau has released details of the initial quote and...
Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE
China-based Qilu Pharmaceutical has announced that its market approval filing for a biosimilar version of...
RemeGen’s Telitacicept Gains FDA Approval for Phase III Study in Myasthenia Gravis
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced receiving approval from the US...
Luye Pharma Gains CDE Approval for Goserelin Acetate Microspheres Clinical Study
China-based Luye Pharma Group (HKG: 2186) has announced receiving approval from the Center for Drug...
Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy
Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has...
CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...
Zennova Pharmaceuticals Completes Phase 1 of Chengdu Manufacturing and R&D Center
Zennova Pharmaceuticals Group, a contract manufacturing organization (CMO) with operations in New Jersey, US, and...
Tigermed Completes Acquisition of Croatia-Based CRO Marti Farm
China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the completion of...
China Unveils Measures to Boost Foreign Investment in R&D Centers
The Ministry of Commerce and Ministry of Science and Technology, with the agreement of the...
Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
RemeGen and Allist Partner to Assess ADC and EGFR Inhibitor Combination in NSCLC
China-based RemeGen Ltd (HKG: 9995) and Allist Pharmaceuticals Inc. (SHA: 688578) have announced a clinical...